Related Experiment Video
Updated: Nov 21, 2025

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
Published on: February 10, 2023
Probing biased activation of mu-opioid receptor by the biased agonist PZM21 using all atom molecular dynamics
Siyan Liao1, Kai Tan2, Cecilia Floyd3
1Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China; College of Science and Mathematics, Rowan University, Glassboro, NJ 08028, USA.
Abstract:
Morphine is a commonly used opioid drug to treat acute pain by binding to the mu-opioid receptor (MOR), but its effective analgesic efficacy via triggering of the heterotrimeric Gi protein pathway is accompanied by a series of adverse side effects via triggering of the β-arrestin pathway. Recently, PZM21, a recently developed MOR biased agonist, shows preferentially activating the G protein pathway over β-arrestin pathway. However, there is no high-resolution receptor structure in complex with PZM21 and its action mechanism remains elusive. In this study, PZM21 and Morphine were docked to the active human MOR-1 homology structure and then subjected to the molecular dynamics (MD) simulations in two different situations (i.e., one situation includes the crystal waters but another does not). Detailed comparisons between the two systems were made to characterize the differences in protein-ligand interactions, protein secondary and tertiary structures and dynamics networks. PZM21 could strongly interact with Y3287.43 of TM7, besides the residues (Asp1493.32 and Tyr1503.33) of TM3. The two systems' network paths to the intracellular end of TM6 were roughly similar but the paths to the end of TM7 were different. The PZM21-bound MOR's intracellular ends of TM5-7 bent outward more along with the distance changes of the three key molecular switches (ionic lock, transmission and Tyr toggle) and the distance increase of some conserved inter-helical residue pairs. The larger intracellular opening of the receptor could potentially facilitate G protein binding.
Insights
PZM21, a biased agonist, preferentially activates the mu-opioid receptor (MOR) G protein pathway over the β-arrestin pathway. Molecular dynamics simulations reveal PZM21 binding induces conformational changes facilitating G protein interaction, potentially reducing side effects.
Area of Science:
- Pharmacology
- Structural Biology
- Computational Chemistry
Background:
- Morphine, a mu-opioid receptor (MOR) agonist, treats pain but causes side effects via β-arrestin pathway activation.
- PZM21 is a novel MOR-biased agonist designed to favor G protein signaling over β-arrestin signaling.
Purpose of the Study:
- To elucidate the molecular mechanism of PZM21 action at the MOR.
- To compare PZM21 and morphine binding and activation dynamics.
Main Methods:
- Molecular docking of PZM21 and morphine to a human MOR homology model.
- Molecular dynamics (MD) simulations with and without crystal waters.
- Analysis of protein-ligand interactions, structural dynamics, and signaling pathways.
Main Results:
- PZM21 strongly interacts with MOR residues Y328(7.43), Asp149(3.32), and Tyr150(3.33).
- PZM21 binding causes outward bending of MOR intracellular TM5-7 helices, distinct from morphine.
- Simulation results suggest PZM21 binding creates a larger intracellular cavity, potentially enhancing G protein coupling.
Conclusions:
- PZM21's biased agonism is structurally supported by distinct MOR conformational changes.
- The observed structural dynamics provide insights into PZM21's preferential G protein pathway activation.
- This study offers a structural basis for developing safer analgesics targeting the MOR.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Related Concept Videos
Opioid Receptors: Overview
Analgesia and Pain Management
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Cooperative Allosteric Transitions